DDInter1822 DDInter1725
Aminoglycosides, many of which are derived directly from _Streptomyces_ spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic _Pseudomonas aeruginosa_ infections in cystic fibrosis patients, as _P. aeruginosa_ is notoriously inherently resistant to many antibiotics.[A232294, A232299, L32739] However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria.[L32744, L32749] Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.[A232294, A232349, L
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970. Although sulfasalazine is only approved by the FDA for ulcerative colitis, research have shown that sulfasalazine is also beneficial for patients with Crohn's disease. Meta-analysis of 19 randomized controlled trials indicated that sulfasalazine is superior to placebo in inducing remission; however, with no supported evidence of mucosal healing, sulfasalazine is not FDA-recommmended for treatment of Crohn's disease.[A255597,A255602,A255607]
Tobramycin {u} (Compound) resembles {v} (Compound) Gentamicin
Gentamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Tobramycin {u} (Compound) resembles {v} (Compound) Gentamicin
Gentamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olsalazine
Olsalazine {u} (Compound) resembles {v} (Compound) Sulfasalazine
Tobramycin {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Vismodegib
Vismodegib {u} (Compound) resembles {v} (Compound) Sulfasalazine
Tobramycin {u} (Compound) resembles {v} (Compound) Gentamicin
Gentamicin {u} (Compound) downregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is downregulated by {v} (Compound) Sulfasalazine
Tobramycin {u} (Compound) resembles {v} (Compound) Neomycin
Neomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mestranol
Mestranol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Tobramycin {u} (Compound) resembles {v} (Compound) Neomycin
Neomycin {u} may lead to a major life threatening interaction when taken with {v} Polymyxin B
Polymyxin B {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Tobramycin {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Folic acid
Folic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfasalazine
Tobramycin {u} (Compound) resembles {v} (Compound) Kanamycin
Kanamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenylbutazone
Phenylbutazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Tobramycin {u} (Compound) resembles {v} (Compound) Gentamicin
Gentamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketorolac
Ketorolac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Tobramycin {u} (Compound) causes {v} (Side Effect) Weight decreased
Weight decreased {u} (Side Effect) is caused by {v} (Compound) Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Tobramycin (Compound) resembles Gentamicin (Compound) and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Tobramycin (Compound) resembles Gentamicin (Compound) and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine (Compound) resembles Sulfasalazine (Compound)
Tobramycin (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Vismodegib (Compound) and Vismodegib (Compound) resembles Sulfasalazine (Compound)
Tobramycin (Compound) resembles Gentamicin (Compound) and Gentamicin (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is downregulated by Sulfasalazine (Compound)
Tobramycin (Compound) resembles Neomycin (Compound) and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Mestranol and Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Tobramycin (Compound) resembles Neomycin (Compound) and Neomycin may lead to a major life threatening interaction when taken with Polymyxin B and Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Tobramycin (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Folic acid (Compound) and Folic acid may cause a minor interaction that can limit clinical effects when taken with Sulfasalazine
Tobramycin (Compound) resembles Kanamycin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Tobramycin (Compound) resembles Gentamicin (Compound) and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Tobramycin (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Naltrexone (Compound) and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine